Email ID : 
Password : 
Forgot Your Password ? 

Only Report Titles
Titles & Keywords
NOTE: Site best viewed with Internet Explorer
  CONTRACEPTIVES
A Global Strategic Business Report

This report analyzes the worldwide markets for Contraceptives in Millions of US$. The specific product segments analyzed are Oral Contraceptives, Condoms, Implants/ Injections, and Others. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, Latin America, and Rest of World. Annual forecasts are provided for each region for the period of 2000 through 2015. The report profiles 165 companies including many key and niche players worldwide such as Ansell Limited, Barr Pharmaceuticals, Inc., Church & Dwight Co. Inc., Conceptus, Inc., Condomi Health International GmbH, Female Health Company, Fuji Latex Co., Johnson & Johnson, Ortho-McNeil Pharmaceutical Inc, Okamoto Industries, Inc., Schering-Plough Corporation, Organon USA Inc, Bayer Schering Pharma AG, SSL International PLC, Warner Chilcott PLC, and Wyeth Corporation. Market data and analytics are derived from primary and secondary research. Company profiles are mostly extracted from URL research and reported select online sources.

CODE:    MCP-2528  PAGES:    503
PRICE:    $3950  DATE:       March 2008
COMPANIES:  165  MARKET DATA TABLES:   204
Due to the proprietary nature, our previews are offered only to manufacturers, top-tier management consultants, investment banks, and investment research groups.

 TABLE OF CONTENTS  
  CONTRACEPTIVES (Complete Report) Pages : 503   | $3950
I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS4$100
   Study Reliability and Reporting Limitations.....I-1  
   Disclaimers.....I-2
Data Interpretation & Reporting Level.....I-2
  
   Quantitative Techniques & Analytics.....I-3
Product Definitions and Scope of Study.....I-3
Oral Contraceptives.....I-3
Condoms.....I-3
  
   Implants/Injections.....I-4
Other Contraceptives.....I-4
  
II. EXECUTIVE SUMMARY125$2250
  1. Outlook.....II-18 $800  
   Table 1: Global Contraceptive Market (2004): Percentage Market Share Breakdown of Leading Players - Schering AG, Johnson & Johnson, Barr Pharmaceuticals, Akzo Nobel, Watson Labs, Wyeth Laboratories, and Others (includes corresponding Graph/Chart).....II-21$300
   Multifunctional Modern Contraceptives Make a Foray.....II-3
Top 5 Brands in the World Hormonal Contraceptives Market As of the Year 2005.....II-3
Extensive Distribution Drives growth of Contraceptive Products.....II-3
1$100
   Advertising for Contraceptives Acquires A Whole New Dimension.....II-4
Manufacturers & Retailers Work in Sync to Accelerate Sales.....II-4
Innovation Keeps the Fire Burning for the Condoms Market.....II-4
1$100
   Hormonal Contraceptives – Select Trends.....II-5
Table 2: Global Female Contraception Market (2004): Percentage Share Breakdown of Select Geographic Markets – United States, Europe, Latin America/ Canada, Japan, and Rest of World (includes corresponding Graph/Chart).....II-5
Generic & Biosimilar Contraceptive Products Gain Ground.....II-5
Generics Manufacturers.....II-5
1$300
   Key Players in the Generic Hormonal Contraceptives Market.....II-6
Select Players in the Branded Biosimilar Hormonal Contraceptives Market in Developing
  Countries.....II-6
OTC Hormonal Contraceptives – An Attractive Market.....II-6
R&D Companies & Generic Manufacturers - Developing Countries.....II-6
1$100
   Commercial Success of R&D Brands Sustain Developmental Programs in Developing
  Countries.....II-7
1$100
   Challenges Facing Generic Contraceptive Products Manufacturers.....II-8
1$100
  2. Product Overview and Analysis.....II-947 $1500  
   Types of Contraception.....II-9
The Contraceptive Timeline.....II-9
1$100
   Table 3: World Contraceptive Prevalence (2005): Percentage Use of Select Contraception Methods In Less Developed and Developed Regions - Traditional Method, Pill, IUD, Condom, Implant/Injectables, Male Sterilization, Female Sterilization (includes corresponding Graph/Chart).....II-10
Classification.....II-10
By Function.....II-10
Barrier Contraceptives.....II-10
Characteristic Features of Barrier Methods.....II-10
1$300
   Hormonal Contraceptives.....II-11
Prescription Contraceptives.....II-11
Oral Contraceptives.....II-11
1$100
   Overview of Oral Contraceptives - Benefits Vs. Risks.....II-12
Usage Levels of OCs in Worldwide Scenario.....II-12
1$100
   Table 4: Percentage of Women in the age group 15-49 using contraception across select regions and countries for the years 2005 and 2006.....II-131$300
   Traditional and Modern.....II-14
Reversible and Permanent.....II-14
1$100
   Table 5: Birth Control Methods and their Use in Major Regions Worldwide.....II-15
Contraception - Levels of Effectiveness.....II-15
Table 6: Effectiveness Index of Contraceptive Measures.....II-15
3$600
   Unmet Need for Contraception.....II-18
Table 7: Worldwide Contraceptives Market: Percentage Share of Unmet Needs (Recent Past Data for 2003) – for Kenya, NE Brazil, Pakistan, Senegal, Turkey, Colombia, Nigeria, Egypt, Indonesia and Morocco (includes corresponding Graph/Chart).....II-18
Segmental Analysis.....II-18
A. Condoms.....II-18
Overview.....II-18
Categories.....II-18
1$300
   Latex Condoms.....II-19
Non-Latex Condoms.....II-19
Skin Condoms.....II-19
Polyurethane (PU) Condoms.....II-19
Table 8: Leading Product Types in the US Condoms Market (2005) –Percentage Share Breakdown for Latex, Synthetic/Polyurethane and Natural (includes corresponding Graph/Chart).....II-19
1$300
   Comparison Between Polyurethane & Latex Condoms.....II-20
Male Condom – Effectiveness of Protection Against STDs.....II-20
Myths & Facts.....II-20
1$100
   Selection & Effective Use of Condoms.....II-21
Condoms in the War Against AIDS.....II-21
Highlights.....II-21
1$100
   Growth Factors.....II-22
Factors Hindering Wide Spread Use of Condoms.....II-22
Measures Aimed at Increasing Usage.....II-22
1$100
   Female Condoms.....II-23
Who are the Main Users?.....II-23
Reality – An Effective Female Condom.....II-23
1$100
   Market Shares: Year 2002 & 2003.....II-24
Table 9: Worldwide Condoms Market: Leading Players (Recent Past Data for 2002 & 2003) – Percentage Share Breakdown by Value Sales – SSL, Ansell, Church & Dwight, Okamoto, and Others (includes corresponding Graph/Chart).....II-24
B. Oral Contraceptives (OCs)/Pills.....II-24
A Peep into the Past.....II-24
1$300
   Synthetic Oral Contraceptives.....II-25
Characteristic Features of Oral Contraceptives (OCs).....II-25
1$100
   Top Brands/Manufacturers of Oral Contraceptive Formulations Containing Levonorgestrel
  0.15 MG/ Ethinyl Estradiol 30 mcg.....II-26
1$100
   Table 10: Leading Methods of Contraception Worldwide – Female sterilization, Intrauterine devices, Oral contraceptives, Condom, Male Sterilization, Injectable contraceptives, and Others (includes corresponding Graph/Chart).....II-27
Bayer Schering Pharma’s “Yasmin”: A Resounding Brand Worldwide.....II-27
1$300
   Table 11: Sales of Bayer Schering Pharma AG's Yasmin, and Yaz for the Years 2007 and 2009 (In Euro Millions).....II-28
Advantages of Using OCs.....II-28
1$300
   Table 12: Leading Methods of Contraception Worldwide – Female sterilization, Intrauterine devices, Oral contraceptives, Condom, Male Sterilization, Injectable contraceptives, and Others (includes corresponding Graph/Chart).....II-29
Effects of Long-Term Use of Ocs.....II-29
Use of OCs/Pills – Myths & Facts.....II-29
1$300
   Oral Contraceptives – Challenges & Strategies to Overcome Problems.....II-30
Factors Associated with Failure of OCs/Pills.....II-30
Health Conditions to be Addressed when Using OCs.....II-30
1$100
   Understanding Risks Associated with Use of OCs.....II-31
Cardiovascular Disease – A Major Side Effect of OC.....II-31
1$100
   Intake of OCs Result in High Blood Pressure.....II-32
Smoking Intensifies Respiratory Problems in Pill Users.....II-32
Complications Arising by Use of OCs Directly Related to Age.....II-32
Relation Between the OC and Cancer.....II-32
Depression Linked to Use of OCs.....II-32
OCs Increases Osteoporosis Risk at Later Stage.....II-32
1$100
   OCs May Reduce Sex Drive.....II-33
Effects of Pill on Childbearing Capacity.....II-33
Visiting a Doctor – Highly Recommended in Case of Warning Symptoms.....II-33
Emergency Contraception (EC) – A New Face of Ocs.....II-33
1$100
   Role of ECPs.....II-34
Effectiveness of ECP.....II-34
Different Types of EC Products.....II-34
Mini Pills.....II-34
1$100
   RU486 - the French Abortion Pill.....II-35
Top Brands/Manufacturers of Emergency Contraceptive Pills Containing
  Levonorgestrel 0.75 mg.....II-35
1$100
   Top Brands/Manufacturers of Emergency Contraceptive Pills Containing Levonorgestrel
  10.25mg and Ethinyl Estradiol 50mcg.....II-36
Availability of Hormonal Contraceptives as OTC Drugs.....II-36
C. Injectable Contraceptives.....II-36
1$100
   Depo-Provera.....II-37
Characteristic Features of Injectable Contraceptives.....II-37
1$100
   Injectables – Challenges & Strategies to Overcome Problems.....II-38
Top Brands & Manufacturers of Two & Three Month Injectable Contraceptive
  Formulations Containing Depot Medroxyprogesterone Acetate (DMPA), and
    Norethisterone Enanthate.....II-38
1$100
   Top Brands & Manufacturers of Monthly Injectable Contraceptive Formulations
  Containing (Norethisterone Enanthate 50 mg and Estradiol Valerate 5 mg),
    (Dihydroxy Progesterone Acetophenide 75 mg and Estradiol Enanthate 5 mg),
      (Medroxyprogesterone Acetate 25 mg and Estradiol Cypionate 5 mg),
        (Algeston acetophenide 150 mg and Estradiol Enanthate 10 mg), and
          Hydroxiprogesterone Caproate 250 mg.....II-39
1$100
   D. Intrauterine Devices (IUDs)/Implants.....II-40
Product Categories.....II-40
CopperT 380A (ParaGard).....II-40
1$100
   Progesterone T (or Progestasert).....II-41
Characteristic Features.....II-41
Benefits.....II-41
1$100
   Side Effects.....II-42
Challenges & Strategies to Overcome Problems.....II-42
1$100
   Table 13: IUD Users Worldwide (2005): Percentage Breakdown by Select Geographic Country/Region (includes corresponding Graph/Chart).....II-43
Long-term Reversible Contraceptive Implants.....II-43
Products.....II-43
Norplant.....II-43
1$300
   Implanon.....II-44
Mirena.....II-44
Characteristic Features of Implantable Contraceptives.....II-44
1$100
   Challenges & Strategies to Overcome Problems.....II-45
E. Spermicides.....II-45
Product Categories.....II-45
1$100
   Benefits.....II-46
Drawbacks.....II-46
Contraceptive Foam.....II-46
Delfen Contraceptive Foam.....II-46
Contraceptive Cream or Jelly.....II-46
Encare Ovals.....II-46
F. Diaphragms.....II-46
1$100
   G. Withdrawal & Douching.....II-47
H. Sterilization.....II-47
Tubal Ligation.....II-47
1$100
   Reasons Behind Adoption.....II-48
Risk of Complications.....II-48
Types.....II-48
Abdominal Procedures.....II-48
Laparoscopy.....II-48
1$100
   Mini-Laparotomy.....II-49
Laparotomy.....II-49
Vaginal Procedures.....II-49
Culdoscopy.....II-49
Colpotomy.....II-49
Hysterectomy – A High Risk Surgery.....II-49
1$100
   Selective Tubal Occlusion Procedure (STOP).....II-50
Vasectomy.....II-50
Method of Working.....II-50
1$100
   Reasons Behind Adoption.....II-51
Risk of Complications.....II-51
I. Other Contraceptive Methods.....II-51
Contraceptive Sponges.....II-51
1$100
   Today Sponge.....II-52
Characteristic Features of Today Sponge.....II-52
1$100
   Table 14: Efficiency Rates of Today Sponge Based on Usage for 12-Month Period (includes corresponding Graph/Chart).....II-53
Allendale Pharmaceuticals.....II-53
Protectaid Sponge.....II-53
1$300
   Characteristic Features of Protectaid Sponge.....II-54
Cervical Caps.....II-54
Pros and Cons of the Device.....II-54
1$100
   Vaginal Contraceptive Film (VCF).....II-55
Contraceptive Vaccine.....II-55
Ortho Evra Weekly Contraceptive Patch.....II-55
NuvaRing Monthly Vaginal Ring.....II-55
1$100
  3. Research and Development.....II-563 $300  
   University of Kansas Conducts Research on the Male Pill.....II-56
Clinical Trial of Contraceptive Spray.....II-56
1$100
   Oral Contraceptive Minimizes Premenstrual Syndrome Symptoms as per New Study.....II-57
Indian Scientists in Process of Developing First Herbal Contraceptive Pill.....II-57
Cause of Infertility - Not Associated with IUDs.....II-57
Effectiveness of Norplant (Levonorgestrel implant).....II-57
1$100
   Presence of Estrogen in OCs Offers Protection from Colorectal Cancer.....II-58
Hormonal Contraceptive Usage & Risk Associated with Certain STDs.....II-58
Use of Third Generation OCs Increases Risk of Blood Clots.....II-58
High Risk of Deep Vein Thrombosis with Cyproterone-Containing OCs.....II-58
1$100
  4. Role of United Nations in Promoting use of Contraceptives.....II-5916 $1200  
   Female Condoms Reach New Heights with Aid from UNAIDS.....II-59
Donor Support for Contraceptive Commodity.....II-59
Table 15: Total Cost of Contraceptives and Condoms: 2000-2010P (includes corresponding Graph/Chart).....II-59
1$300
   Unmet Need.....II-60
Table 16: Donor Support by Region: 2004 (includes corresponding Graph/Chart).....II-60

Table 17: Contraceptive Donor Support for STI/HIV Prevention by Agency: 1997-2004.....II-60
1$300
   Donor Support by Contraceptive Method.....II-61
Table 18: Donor Support by Contraceptive Method: 2000-2004 (includes corresponding Graph/Chart).....II-61

Table 19: Donor Support for Contraceptive Method by Agency: 2000-2004 (includes corresponding Graph/Chart).....II-61
1$300
   Donor Support by Top Ten Countries.....II-62
Table 20: Major Donor Support Recipient Countries: 2004 (includes corresponding Graph/Chart).....II-62

Table 21: Donor Support for Condoms and Other Contraceptive Commodities: 1997-2004 (includes corresponding Graph/Chart).....II-62
1$300
   Donor Funding For Male Condoms.....II-63
Table 22: Donor Funding For Male Condoms: 2000-2004 (includes corresponding Graph/Chart).....II-63

Table 23: Donor Funding For Male Condoms by Region: 2004 (includes corresponding Graph/Chart).....II-63
1$300
   Table 24: Number of Male Condoms Supplied by Donors: Region-Wise Breakup for year 2004.....II-641$300
   Table 25: Donor Support for Condoms (1995-2004): Number of Condoms by Donor – USAID, UNFPA, BMZ/KfW, DFID, EU, DKT, PSI, IPPF, MSI, Netherlands, SIDA, and Japan (In Thousand Units) (includes corresponding Graph/Chart).....II-651$300
   Table 26: Donor Funding for Condoms (1995-2004): Number of Condoms by Donor – USAID, UNFPA, BMZ/KfW, DFID, EU, DKT, PSI, IPPF, MSI, Netherlands, SIDA, and Japan (In US$ 000) (includes corresponding Graph/Chart).....II-66

Table 27: Total Number of Female Condoms in Private and Public Sectors: Region-wise Split from Years 1997 through 2004 (includes corresponding Graph/Chart).....II-66
1$300
   Table 28: Percentage of Couples Using Condoms for Family Planning (2005) by Region.....II-672$400
   Use of Modern Contraceptives Grows in Developing Regions.....II-69
Table 29: Estimated Numbers of Contraceptive Users in Developing Nations: 2000-2015 (includes corresponding Graph/Chart).....II-69
1$300
   Table 30: Comparative Study of Modern Contraception Methods in Developing Regions (including India & China) and Developing Regions (excluding India & China) - Percentage of Married Women Using Oral Contraceptives, Female Sterilization, and Intrauterine Devices (IUDs): Recent Past Data for 2000 (includes corresponding Graph/Chart).....II-70
Difference in Usage of Oral Contraceptives in Developed and Developing World.....II-70
Table 31: Oral Contraceptives Usage by Married and Sexually Active Unmarried Women (Aged 15-49 years) in Developed Regions including North America, Eastern Europe & Central Asia, and Australia & New Zealand: Recent Past Data for 2000.....II-70

Table 32: Oral Contraceptives Usage by Married and Sexually Active Unmarried Women (Aged 15-49 years) in Developing Regions including Asia, Near East & North Africa, Sub-Saharan Africa, Pacific Rim, and Latin America & Caribbean: Recent Past Data for 2000 (includes corresponding Graph/Chart).....II-70
1$300
   Prevalence of Contraceptive Methods.....II-71
Table 33: Increase in Contraceptive Usage by 2005 – Percentage Share Growth by Asia, Latin America and Africa (includes corresponding Graph/Chart).....II-71

Table 34: Worldwide Contraceptives Market: Estimated Number of Users (2015 & 2025) – Asia, Latin America and Africa (includes corresponding Graph/Chart).....II-71
1$300
   Table 35: Worldwide Contraceptive Market: Prevalence Amongst Women (2000-2025) – Percentage Share by Asia, Latin America and Africa (includes corresponding Graph/Chart).....II-72
United Nations Population Fund (UNFPA).....II-72
1$300
   UNFPA Gets Aid from Britain to Help Developing World.....II-73
Rise in Cost of Providing Contraceptives.....II-73
1$100
   Future Trends Worldwide.....II-74
1$100
  5. New Product Introductions/Innovations.....II-7511 $700  
   FHI and HLL Launch Aastha Condom.....II-75
NATCO Launches World-Class Oral Contraceptive.....II-75
Bayer Plans Launch of Mirena in Japan.....II-75
Barr Pharmaceuticals Unveils Generic Version of SEASONALE®.....II-75
PSI Launches Trust Condoms in Uganda.....II-75
1$100
   Tanzania Marketing and Communication Launches a New Brand of Condoms.....II-76
German Group to Launch Innovative Spray-on Condom.....II-76
Hindustan Latex Unveils First-Ever Female Condom in Indian Market.....II-76
Church & Dwight’s Trojan Launches Unique Twister Condom.....II-76
Berlex Inc. Introduces New Oral Contraceptive in the United States.....II-76
Hindustan Latex Launches the Moods ‘Get Closer Pack’.....II-76
1$100
   Warner Introduces First-of-its-Kind Chewable Oral Contraceptive.....II-77
Warner Announces FDA Approval for Loestrin® 24 Fe Contraceptive Pill.....II-77
Huge Brand Unveils "Huge" Brand of Condoms.....II-77
Private Media Group and Zemtex Introduces Private Brand of Condoms.....II-77
1$100
   Hindustan Latex Launches New Varieties of ‘Moods’ Condom.....II-78
Organon Introduces Marvelon 21, Oral Contraceptive in Japan.....II-78
GlaxoSmithKline India Unveils Elogen, a Low Dose Contraception Pill.....II-78
USAID’s T-MARC Launches Two Female Contraceptives in Tanzania.....II-78
1$100
   SMC Plans to Introduce First Implantable Male Contraceptive.....II-79
Zimbabwe in Alliance with Indian Company Launches New Oral Contraceptive
  Products.....II-79
Global Protection Adds “ONE Condoms(C)” to its Product Line.....II-79
Hubei Pharmaceutical Launches a New Contraceptive.....II-79
Intellx Inc Announces Expansion of VA Women's Condom.....II-79
DKT Ethiopia Re-Launches Sensation Condoms.....II-79
Transdermal Contraceptive Spray under Clinical Testing by Population Council and
  Acrux.....II-79
1$100
   Prasco Launches Cesia, a New Generic Oral Contraceptive.....II-80
FHC Launches Female Condom in India.....II-80
FHC Files Patent for Second-Generation Version of the Female Condom.....II-80
FHCO Enters into Agreement with USAID.....II-80
Barr Laboratories Launches Extended-Cycle Oral Contraceptive, Seasonale.....II-80
1$100
   Central Drug Research Institute to Launch Consap.....II-81
Johnson & Johnson Introduces Evra in UK.....II-81
Allendale Pharmaceuticals Relaunches Today Sponge.....II-81
New V-Amour Women's Condom Introduced in Germany.....II-81
Durex Introduces Intense Sensation Condoms.....II-81
Durex Launches Performax Condoms.....II-81
Ortho-McNeil Introduces Ortho Evra.....II-81
1$100
   Pasante Healthcare Launches Pasante Condoms Range.....II-82
Hindustan Latex Debuts New Lubricated Condoms.....II-82
Durex Launches 'Easy-on' line of Condoms.....II-82
Rayson Healthcare Introduces new Condom Brand.....II-82
Ansell healthcare Unveils Contempo Lubricated Latex Condoms.....II-82
Church & Dwight Launches Trojan Her Pleasure Premium Latex Condoms.....II-82
Pharmacia Introduces Depo-Provera contraceptive in 1ml vials.....II-82
Organon Debuts NuvaRing contraceptive.....II-82
1$100
   Organon Laboratories Introduces Cerazette.....II-83
Barr Rolls Out Lessina Contraceptive Tablets.....II-83
Schering Introduces Yasmin Across the US and Europe.....II-83
Condomania Introduces New Packaging.....II-83
Condomania Launches Newly Designed, InSpiral Condoms.....II-83
Condomania Introduces Pleasure Plus Condoms.....II-83
Durex Consumer Launches Two New Varieties.....II-83
Church & Dwight’s Consumer Products Division Launches Two Innovative Products.....II-83
1$100
   Ansell Launches LifeStyles Luscious Flavors Condoms.....II-84
Trojan Introduces Extended Pleasure Premium Latex Condoms.....II-84
JK Ansell Launches New Sub-Brand, Kamasutra Sport.....II-84
JK Ansell Launches Kamasutra Xtra Pleasure Condoms.....II-84
TTK-LIG Launches Pink Version of Kohinoor Luxury Condoms.....II-84
Condomi Launches Vegan-Friendly Condoms in UK.....II-84
Berlex Launches Mirena in US.....II-84
1$100
   Schering Introduces Levonelle in UK.....II-85
Organon Launches Cyclessa.....II-85
Barr Laboratories Launches New Generic Oral Contraceptives in the US.....II-85
Duramed Introduces New Oral Contraceptives in the US.....II-85
American Pharmaceutical Partners Launch New Product.....II-85
Swiss Health Launches Vitex Agnus Castus.....II-85
Sun Pharmaceutical Launches Puregest Progesterone Capsules.....II-85
1$100
  6. Recent Industry Activity.....II-8620 $1000  
   Organon Licenses Spray Technology from Acrux.....II-86
BioSante Initiates Phase II Trials of Oral Contraceptives.....II-86
YAZ® Receives FDA Approval for New Indication.....II-86
Paladin Labs Receives Approval to Market SEASONALE®.....II-86
1$100
   ENJUVIA(TM) (Synthetic Conjugated Estrogens, B) Receives Two FDA Approvals
  (USA).....II-87
Conceptus Receives FDA Approval for Third-Generation Essure ® Procedure.....II-87
Wyeth Receives FDA Approval for Lybrel ™.....II-87
NuvaRing® Completes European Authorization in 13 Countries.....II-87
HLL Expands Promotion of Female Condom.....II-87
1$100
   ChrysCapital Gains Minority Stake in Mankind Pharma.....II-88
7 Chemicals Inks Deal with Ferring Pharmaceuticals.....II-88
Synova Acquires Allendale Pharmaceuticals and Global Rights to Today Sponge.....II-88
Ansell Pockets Blowtex.....II-88
Bayer Merges with Berlex to Establish Bayer HealthCare Pharmaceuticals.....II-88
1$100
   UNFPA Releases Pacific-Design Condoms.....II-89
Wyeth Completes Acquisition of Wyeth K.K. Japan.....II-89
Conceptus, Inc. to Acquire Conceptus SAS.....II-89
Warner Chilcott Company Enters into a Supply Agreement with Watson Pharma.....II-89
SSL International Fully Acquires Qingdao London Durex Co Ltd.....II-89
Bayer HealthCare Takes Over Marketing/Distribution Network of Pharmonyx Ltd......II-89
1$100
   USFDA Grants OTC Status Plan B (R).....II-90
Ethiopia Enters into Agreement with UNFPA and UNICEF.....II-90
YAZ® Receives FDA Approval.....II-90
FHC Receives USAID Orders.....II-90
FHC Signs MoU with Hindustan Latex Ltd......II-90
1$100
   IMPLANON™ Receives US FDA Approval.....II-91
Watson Pharmaceuticals Receives Approval for Generic Version of Seasonale®.....II-91
Watson Pharmaceuticals Receives Approval for Generic Version of Levlite®.....II-91
Ansell Acquires Stake in Wuhan Jissbon Sanitary Products.....II-91
Ansell Acquires Unimil of Poland.....II-91
Conceptus Joins Hands with Gyrus and Olympus on Hysteroscopy.....II-91
1$100
   Watson Acquires Andrx.....II-92
Bayer Acquires Schering AG.....II-92
Duramed Acquires FEI.....II-92
1$100
   Schering and Organon to Terminate Research Collaboration.....II-93
ACR Extends Existing Agreement with Population Council.....II-93
Antares Inks Contraceptive Development Agreement with Population Council.....II-93
FHC to Enhance Manufacturing Capacity of FC2 Female Condom.....II-93
1$100
   Medevice 3S Establishes Condom Manufacturing Facility.....II-94
SSL International to Acquire Additional 50% Stake in Qingdao London Durex in
  China.....II-94
Female Health Company Signs an Agreement with Fuji Latex.....II-94
Female Health Company Obtains Order for the Supply of Female Condoms from
  India.....II-94
Conceptus Receives Cigna’s Approval for Reimbursement of Essure Procedure.....II-94
1$100
   Barr Pharmaceuticals Obtains FDA Approval for Duramed's SEASONIQUE™ Oral
  Contraceptive.....II-95
Schering AG Receives European Approval for Yasminelle® Contraceptives.....II-95
AMMD Takes Over Ovion.....II-95
Duramed Pharmaceuticals Enters into a License and Distribution agreement with
  Paladin.....II-95
Female Health Company Bags Brazilian Order for FC Female Condoms.....II-95
1$100
   Female Health Company Enters into an Agreement with the World YWCA for Distribution of
  FC2 Female Condoms™.....II-96
Akzo Nobels Receives Development and Marketing Rights for EMM 310066
  Contraceptive.....II-96
Conceptus and Gynecare Terminates their Sole Co-Promotion Agreement.....II-96
FTC Sues Warner Chilcott and Barr.....II-96
Acrux Concludes Phase I Clinical Trial for Spray on Contraceptive.....II-96
Vulkan and CPR to Set Up a Joint Venture for the Production of Condoms.....II-96
Warner Chilcott Acquired by Investment Group.....II-96
1$100
   Brazil Based Sao Roque Condoms Plant to Expand Production Capacity.....II-97
Berlex Receives Approval for Yasmin Tablets in Canada.....II-97
Mochida Pharmaceutical to Exclusively Distribute Ortho 777-21 and OrthoM-21 in
  Japan.....II-97
Barr Laboratories Obtains Approval for Demulen Tablet.....II-97
Clinical Trials on Male Contraceptive.....II-97
FHC Receives Distribution Order from South Africa.....II-97
China to Purchase Contraceptives Worth US$ 45.7 Million.....II-97
1$100
   Female Health Company Signs Agreement with BZP.....II-98
Duramed Acquires Exclusive Rights to Nordette® from King Pharmaceuticals.....II-98
Berlex Laboratories Inc. Renamed Berlex, Inc......II-98
Duramed Pharmaceuticals Acquire Rights to Loestrin (R) from Galen.....II-98
Galen Receives Option to License Barr’s Generic Ovcon (R) 35.....II-98
1$100
   Barr Acquires Shares of Women’s Capital Corporation.....II-99
Galen Signs a Licensing Agreement with Barr.....II-99
Galen Acquires Pfizer Manufacturing Facility.....II-99
1$100
   Polar Pharma to Expand Production Capacity and Re-launch ‘Adam’ Condoms.....II-100
Prasco Signs an Agreement with Organon.....II-100
Pfizer Acquires Pharmacia Corp.....II-100
Teva and Andrx in Collaborative Arrangement.....II-100
Barr Laboratories Acquires Marketing Rights.....II-100
Barr Laboratories Signs Mutual Agreement with Galen.....II-100
1$100
   Pfizer Sells Women's Health Care Products to Galen.....II-101
FDA Approves Ovcon 35.....II-101
Barr Obtains FDA Approval for ANDA.....II-101
FHC Enters into an Agreement with HLL.....II-101
Watson Signs an Agreement with OMJ.....II-101
1$100
   Ortho-McNeil Receives Approval for ORTHO TRI- CYCLEN LO.....II-102
American Home Products Restructures and Changes Name to Wyeth Corporation.....II-102
Ansell Promotes the Fun Factor Embarks on ‘It Feels Right’ Campaign.....II-102
FDA’s Approval for Barr's generic Ortho-Cyclen Tablet.....II-102
1$100
   Warner-Chilcott Acquires Two Healthcare Products from Bristol-Myers.....II-103
Ansell Acquires Johnson & Johnson’s Canadian Condom Business.....II-103
SSL Acquires Joint Venture Partner in Seton Scholl Japan Ltd.....II-103
CSI Acquires Plant in North Las Vegas for Condom Production.....II-103
Barr Laboratories Merges with Duramed Pharmaceuticals.....II-103
Condomi Enters into a Strategic Joint Venture.....II-103
1$100
   Condomi in Alliance with MCM.....II-104
FHC Enters into Supply Contract in Brazil.....II-104
FHC Secures Contract from UNFPA.....II-104
FHC Receives Contract from South African Health Department.....II-104
1$100
   Carter Wallace Divests Consumer Brands to Armkel.....II-105
SSL Restructures Business Operations.....II-105
FHC Renames Female Condom.....II-105
US Branch of SSL International Group Renamed.....II-105
1$100
  7. Focus on Select Players.....II-1065 $500  
   Ansell Limited (Australia).....II-106
Barr Pharmaceuticals, Inc. (US).....II-106
Church & Dwight Co Inc (US).....II-106
1$100
   Conceptus Inc (US).....II-107
Condomi Health International GmbH (Germany).....II-107
Female Health Company (US).....II-107
Fuji Latex Co (Japan).....II-107
1$100
   Johnson & Johnson (US).....II-108
Ortho-McNeil Pharmaceutical Inc (US).....II-108
Okamoto Industries Inc (Japan).....II-108
1$100
   Schering-Plough Corporation (US).....II-109
Organon USA Inc (US).....II-109
Bayer Schering Pharma AG (Germany).....II-109
SSL International PLC (UK).....II-109
1$100
   Warner Chilcott PLC (US).....II-110
Wyeth Corporation (US).....II-110
1$100
  8. Global Market Perspective.....II-111   
   Table 36: World Recent Past, Current & Future Analysis for Contraceptives by Geographic Region- US, Canada, Japan, Europe, Asia–Pacific (excluding Japan), Latin America and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart).....II-1111$300
   Table 37: World Long-term Projections for Contraceptives by Geographic Region – US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart).....II-1121$300
   Table 38: World 10-Year Perspective for Contraceptives by Geographic Region- Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, Asia–Pacific (excluding Japan), Latin America and Rest of World Markets for Years 2000, 2007 & 2010 (includes corresponding Graph/Chart).....II-1131$300
   Table 39: World Recent Past, Current & Future Analysis for Oral Contraceptives by Geographic Region- US, Canada, Japan, Europe, Asia–Pacific (excluding Japan), Latin America and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart).....II-1141$300
   Table 40: World Long-term Projections for Oral Contraceptives by Geographic Region – US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart).....II-1151$300
   Table 41: World 10-Year Perspective for Oral Contraceptives by Geographic Region- Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, Asia–Pacific (excluding Japan), Latin America and Rest of World Markets for Years 2000, 2007 & 2010 (includes corresponding Graph/Chart).....II-1161$300
   Table 42: World Recent Past, Current & Future Analysis for Condoms by Geographic Region- US, Canada, Japan, Europe, Asia–Pacific (excluding Japan), Latin America and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart).....II-1171$300
   Table 43: World Long-term Projections for Condoms by Geographic Region – US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart).....II-1181$300
   Table 44: World 10-Year Perspective for Condoms by Geographic Region- Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, Asia–Pacific (excluding Japan), Latin America and Rest of World Markets for Years 2000, 2007 & 2010 (includes corresponding Graph/Chart).....II-1191$300
   Table 45: World Recent Past, Current & Future Analysis for Implants/Injections by Geographic Region- US, Canada, Japan, Europe, Asia–Pacific (excluding Japan), Latin America and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart).....II-1201$300
   Table 46: World Long-term Projections for Implants/Injections by Geographic Region – US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart).....II-1211$300
   Table 47: World 10-Year Perspective for Implants/Injections by Geographic Region- Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, Asia–Pacific (excluding Japan), Latin America and Rest of World Markets for Years 2000, 2007 & 2010 (includes corresponding Graph/Chart).....II-1221$300
   Table 48: World Recent Past, Current & Future Analysis for Other Contraceptives by Geographic Region- US, Canada, Japan, Europe, Asia–Pacific (excluding Japan), Latin America and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart).....II-1231$300
   Table 49: World Long-term Projections for Other Contraceptives by Geographic Region – US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart).....II-1241$300
   Table 50: World 10-Year Perspective for Other Contraceptives by Geographic Region- Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, Asia–Pacific (excluding Japan), Latin America and Rest of World Markets for Years2000, 2007 & 2010 (includes corresponding Graph/Chart).....II-1251$300
III. MARKET132$1950
  1. The United States.....III-144 $1475  
   A. Market Analysis.....III-1
Outlook.....III-1
Restraints.....III-1
Major Market Trends.....III-1
Changing Consumer Demographics.....III-1
1$75
   Relentless Promotional Programs Drive Home the Point.....III-2
Use of Intimacy Products on the Rise.....III-2
Table 51: US Contraceptives Ad Spend (2005): Percentage Breakdown by Dollars Spent on Radio, Out of Home Advertising, Television, Magazine, and Newspaper (includes corresponding Graph/Chart).....III-2
1$150
   Generics Ransack the Branded Market.....III-3
Condoms – A ‘Fun, Inviting and Pleasurable’ Way to Healthy Life and
  Lifestyle.....III-3
Trojan Dominates the Condoms Market in the US.....III-3
1$75
   Market Share Statistics.....III-4
Table 52: US Market for Male Contraceptives: Percentage Breakdown of Retail Dollar Sales of Key Players for the Year Ended January 2007 (includes corresponding Graph/Chart).....III-4

Table 53: US Market for Male Contraceptives: Breakdown of Retail Unit Sales of Key Players for the Year Ended January 2007 (In 000 Units) (includes corresponding Graph/Chart).....III-4
1$150
   Table 54: US Market for Female Contraceptives: Percentage Breakdown of Retail Dollar Sales of Key Players for the Year Ended January 2007 (includes corresponding Graph/Chart).....III-5

Table 55: US Market for Female Contraceptives: Percentage Breakdown of Retail Unit Sales of Key Players for the Year Ended January 2007 (includes corresponding Graph/Chart).....III-5

Table 56: US Market for Female Contraceptives: Percentage Breakdown of Dollar Sales of Leading Brands for the Year Ended March 2005 (includes corresponding Graph/Chart).....III-5
Noticeable Shift in Retail Marketing Techniques.....III-5
1$150
   Rising Use of Condoms Amongst Teenagers.....III-6
Changing Attitudes and Perceptions Drive Market Sales.....III-6
1$75
   Pill Continues to be One of the Most Popular Forms of Contraception.....III-7
Table 57: Leading Methods of Contraception in the US : Percentage Breakdown by Method of Contraception for Oral Contraceptives, Condoms, Female Sterilization, Male Sterilization, Withdrawal, Injectables, Rhythm, Intrauterine Devices, Other(s), and No Method Followed (includes corresponding Graph/Chart).....III-7
1$150
   Oral Contraceptives and its Shades of Grey.....III-8
Marketing Efforts Aimed at Influencing Female College Students.....III-8
Condoms Continuing Canter.....III-8
1$75
   Table 58: US Condoms Market (Recent Past Data for 2003): Consumer Purchasing Patterns for Condoms at All Retail Outlets, Drug Stores, Supermarkets, Supercenters, and Discount Stores (includes corresponding Graph/Chart).....III-9
Drug Stores Remain the Choice for Contraceptive Needs.....III-9
Trade Class Statistics.....III-9
1$150
   Table 59: Leading Male Contraceptives Brands in the US (2005) - Percentage Share Breakdown by Sales Revenues through Drug Stores – Trojan, Trojan Enz, Trojan Magnum, LifeStyles, Durex Extra Sensitive, Trojan Her Pleasure, Kling-Tite Naturalamb, Durex and *Others (includes corresponding Graph/Chart).....III-10

Table 60: Leading Male Contraceptive Brands in the US (2005) - Percentage Share Breakdown by Volume Sales through Drug Stores – Trojan, Trojan Enz, Trojan Magnum, Durex Extra Sensitive, LifeStyles, Trojan Her Pleasure, Durex, Trojan Supra and *Others (includes corresponding Graph/Chart).....III-10
1$150
   Table 61: Leading Brands in the US Condoms Market (2004): Percentage Share Breakdown by Trade Class (Supermarkets, Drug Stores, and Discount Stores (Excluding Wal-Mart)) Sales for Trojan, Trojan Enz, Lifestyles, Durex Extra Sensitive, Trojan Magnum, Trojan Ultra Pleasure, Trojan Her Pleasure, Kling Tite Naturalamb, Trojan Extended Pleasure, Lifestyles Ultra Sensitive, and Others (includes corresponding Graph/Chart).....III-111$150
   Table 62: Leading Drug Store Brands in the US Condoms Market (2003): Percentage Share Breakdown for Trojan, Trojan Enz, LifeStyles, Trojan Magnum, Durex Extra Sensitive, Kling Tite Natural Lamb, Trojan Her Pleasure, Trojan Ultra Pleasure, Trojan Extended Pleasure, Durex, and Others (includes corresponding Graph/Chart).....III-121$150
   Table 63: Leading Supermarket Brands in the US Condoms Market (Recent Past Data for 2001-2003): Percentage Share Breakdown by Trojan, Trojan-Enz, Lifestyles, Sheik Super, Class-Act, Sheik-Classic, Naturalamb and Others (includes corresponding Graph/Chart).....III-13

Table 64: Leading Condom Brands in the US Market (Recent Past Data for 2003): Percentage Breakdown by Trojan, Trojan Enz, Lifestyles, Durex Extra Sensitive, Trojan Ultra Pleasure, Kling Tite Natural lamb, Trojan Magnum, Durex Ultimate Feeling, Trojan Supra and Durex High Sensation (includes corresponding Graph/Chart).....III-13
1$150
   Table 65: Sales of Condoms Through Leading Distribution Channels in the US (2005) -Drug Stores, Discount Stores and Supermarkets (includes corresponding Graph/Chart).....III-14

Table 66: Distribution Channel Percentage Share – US Male Contraceptives (Recent Past Data for 2003 & 2002) – by Chain Drug Stores, Discount Stores, Food/Drug Combination Stores, Independent Drug Stores and Supermarkets (includes corresponding Graph/Chart).....III-14

Table 67: US Contraceptives Market: Average Price per Unit of Male and Female Contraceptives for he Year 2006 (In US $).....III-14
1$150
   Table 68: Total Contraceptives Market in the US (2005) – Percentage Share Breakdown by Trade Class (Supermarkets, Drug Stores, and Discount Stores (Excluding Wal-Mart)) Value Sales for Male Contraceptives and Female Contraceptives.....III-15

Table 69: US Condoms Market: Percentage Breakdown of Dollar Sales by Product Type for the Year Ended January 2006 (includes corresponding Graph/Chart).....III-15
Oral Contraceptives – Unanimously the Choice of American Women.....III-15
Table 70: Contraceptive Features Preferred by Women in US (includes corresponding Graph/Chart).....III-15
1$150
   Table 71: US Market for Oral Contraceptive Drugs (2004): Percentage Breakdown of Dollar Sales of Leading Brands (includes corresponding Graph/Chart).....III-16

Table 72: US Market for Oral Contraceptive Drugs (2004): Breakdown of Leading Brands by Total Number of Prescriptions (TRx) (In Million) (includes corresponding Graph/Chart).....III-16
1$150
   Table 73: US Oral Contraceptive Market: Percentage Breakdown of Dollar Sales of Branded Oral Contraceptives and Branded-Generic Oral Contraceptives for the Years 2002 & 2004.....III-17

Table 74: US Market for New Prescription (NRx) Oral Contraceptive (Estrogen/Progestogen-based) Drugs (2006): Percentage Market Share Breakdown of Leading Players (includes corresponding Graph/Chart).....III-17

Table 75: US Market for Prescription (Rx) Oral Contraceptives: Percentage Market Share Breakdown of Leading Players for the Years 2007E and 2010(P) (includes corresponding Graph/Chart).....III-17
1$150
   Table 76: US Prescription Contraceptives Market: Percentage Market Share Breakdown for Select Product Categories for the Years 2007E & 2010P (includes corresponding Graph/Chart).....III-18

Table 77: US Market for Prescription Extended Cycle Oral Contraceptives: Percentage Market Share Breakdown for Leading Brands for the Years 2007E & 2010P (includes corresponding Graph/Chart).....III-18
1$150
   Export & Import Statistics.....III-19
Table 78: US Exports of Chemical Contraceptive Preparations (Based on Hormones or Spermicides): Breakdown of Export Value by Select Destination Countries for the Year 2006 (In US $ Thousand) (includes corresponding Graph/Chart).....III-19
1$150
   Table 79: US Imports of Chemical Contraceptive Preparations (Based on Hormones or Spermicides): Breakdown of Import Value by Select Countries of Origin for the Year 2006(In US $ Thousand) (includes corresponding Graph/Chart).....III-20

Table 80: US Exports of Sheath Contraceptives made of Vulcanized Rubber (other than hard rubber) : Breakdown of Export Value by Select Destination Countries for the Year 2006(In US $ Thousand) (includes corresponding Graph/Chart).....III-20
1$150
   Table 81: US Imports of Sheath Contraceptives made of Vulcanized Rubber (other than hard rubber): Breakdown of Import Value by Select Countries of Origin for the Year 2006(In US $ Thousand) (includes corresponding Graph/Chart).....III-21

Table 82: Contraceptives Market in the US: Leading Hormonal Contraceptives (Recent Past Data for 2002) – Percentage Share by Developer/Marketer: J&J, Wyeth Corp, Schering AG, Akzo Nobel’s Organon, Pharmacia and Pfizer (includes corresponding Graph/Chart).....III-21
1$150
   Health Facts.....III-22
Rising Use of Oral Contraceptives.....III-22
Abortion Control Drugs & Methods.....III-22
Medical Abortion.....III-22
a. Mifepristone - A Medical Breakthrough.....III-22
1$75
   b. Methotrexate.....III-23
Expanding the Use & Availability of EC Drugs.....III-23
Pharmacies Sell ECPs.....III-23
Demographics.....III-23
Facts and Figures.....III-23
1$75
   Sales of Contraceptives (Male & Female) – Family Planning Category.....III-24
Insurance Coverage for Contraceptives Still in Contest.....III-24
Key Players.....III-24
4$225
   Product Launches.....III-283$175
   Strategic Corporate Developments.....III-3112$500
   B. Market Analytics.....III-43
Table 83: US Recent Past, Current & Future Analysis for Contraceptives by Product Segment- Oral Contraceptives, Condoms, Implants/Injections and Others Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart).....III-43

Table 84: US Long-term Projections for Contraceptives by Product Segment – Oral Contraceptives, Condoms, Implants/Injections and Others Markets Segments Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart).....III-43
1$150
   Table 85: US 10-Year Perspective for Contraceptives by Product Segment – Percentage Breakdown of Dollar Sales for Oral Contraceptives, Condoms, Implants/Injections and Others Markets for 2000, 2007 & 2010 (includes corresponding Graph/Chart).....III-44
1$150
  2. Canada.....III-456 $650  
   A. Market Analysis.....III-45
Scenario.....III-45
Efforts on Way to Launch Male Contraceptive Injection.....III-45
Outlook.....III-45
Condoms Market.....III-45
1$75
   Immucon Obtains US Patent for Male Contraceptive Technology.....III-46
Exports & Import Statistics.....III-46
Table 86: Canadian Exports of Chemical Contraceptive Preparations (Based on Hormones or Spermicides): Percentage Breakdown of Export Value by Select Destination Countries for the Year 2005 (includes corresponding Graph/Chart).....III-46
1$150
   Table 87: Canadian Imports of Chemical Contraceptive Preparations (Based on Hormones or Spermicides): Percentage Breakdown of Import Value by Select Countries of Origin for the Year 2005 (includes corresponding Graph/Chart).....III-47

Table 88: Canadian Exports of Sheath Contraceptives made of Vulcanized Rubber (other than hard rubber): Percentage Breakdown of Export Value by Select Destination Countries for the Year 2005 (includes corresponding Graph/Chart).....III-47
1$150
   Table 89: Canadian Imports of Sheath Contraceptives made of Vulcanized Rubber (other than hard rubber): Percentage Breakdown of Import Value by Select Countries of Origin for the Year 2005 (includes corresponding Graph/Chart).....III-48
Strategic Corporate Developments.....III-48
1$150
   B. Market Analytics.....III-49
Table 90: Canadian Recent Past, Current & Future Analysis for Contraceptives by Product Segment- Oral Contraceptives, Condoms, Implants/Injections and Others Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart).....III-49
1$150
   Table 91: Canada Long-term Projections for Contraceptives by Product Segment – Oral Contraceptives, Condoms, Implants/Injections and Others Markets Segments Independently Analyzed with Annual Sales Figures in US$ Mi